Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma

Interventional Neuroradiology

Volumn 17, Issue 4, 2011, Pages 459-465

  Rajappa, P ^a   Krass, J ^a,b   Riina, H A ^c   Boockvar, J A ^a   Greenfield, Jeffrey P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basilar artery; Bevacizumab; Ependymoma; Infusions; Intra arterial

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MK 0752; VINCRISTINE;

ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION SURGERY; EPENDYMOMA; GUIDE WIRE; HUMAN; INFUSION; MALE; MULTIPLE RECURRENT EPENDYMOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; REOPERATION; STEREOTACTIC RADIATION THERAPY; SUPER SELECTIVE BASILAR ARTERY INFUSION; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

EID: 84855600808     PISSN: 15910199     EISSN: None     Source Type: Journal    
DOI: 10.1177/159101991101700410     Document Type: Article

References (21)

1. Wright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst. 2009; 25 (10): 1275-82.
2. Karajannis M, Allen JC, Newcomb EW. Treatment of pediatric brain tumors. J Cell Physiol. 2008; 217: 584-589.
3. Robertson RL, Zeltzer PM, Boyett JM, et al., Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998; 88: 695-703. (Pubitemid 28145213)
4. Sutton LN, Goldwein J, Perilongo G et al. Prognostic factors in childhood ependymomas. Pediatr Neurosurg. 1990; 16: 57-65.
5. Goldwein JW, Glauser TA, Packer RJ, et al., Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer. 1990; 66: 557-563. (Pubitemid 20233456)
6. Mason WP, Goldman S, Yates AJ, et al., Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma a report of the Children's Cancer Group. J Neurooncol. 1998; 37: 135-143. (Pubitemid 28073586)
7. Strother DR PI, FR, Hunter JV, Woo SY, et al. Tumors of the central nervous system. In: Principles and practice of pediatric oncology. New York: Lipincott Williams & Wilkins; 2003. 778-785.
8. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst. 1999; 15: 563-570. (Pubitemid 29493582)
9. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature reviews. Cancer. 2002; 2: 727-739. (Pubitemid 37328908)
10. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006; 312: 1171-1175. (Pubitemid 43801134)
11. Riina HA, Knopman J, Greenfield JP, et al., Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interventional Neuroradiology 2010; 16: 71-76.
12. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006; 66: 7843-7848. (Pubitemid 44299144)
13. Green RM, Cloughesey TF, Stupp R, et al., Bevacizumab for recurrent ependymoma. Neurology. 2009; 73: 1677-16780.
14. Pediatric Brain Tumor Consortium; National Cancer Institute (NCI). MK0752 in treating young patients with recurrent or refractory cns cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 20110725]. Available from: URL of the record NLM Identifier: NCT00572182.
15. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999; 21: 203-211. (Pubitemid 30306031)
16. Pollack IF, Gertszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995; 37: 655-666; discussion 666-667.
17. Merchant TE. Current management of childhood ependymoma. Oncology. 2002; 16: 629-642, 644; discussion 645-646, 648.
18. Nazar GB, Hoffman HJ, Becker LE, et al., Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg. 1990; 72: 408-417. (Pubitemid 20072964)
19. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, et al. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol, 1996; 27 (1): 8-14.
20. Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst. 2009; 25 (10): 1293-1301.
21. Gobin YP, Cloughesey TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 2001; 218 (3): 724-732. (Pubitemid 32172554)